Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung CancerÓscar Arrieta, Rafael Rosell, Feliciano Barrón et al.|JAMA Oncology|2020Cited by 153
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i>-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN StudyBenjamin Solomon, Tony Mok, Hidetoshi Hayashi et al.|Journal of Clinical Oncology|2022Cited by 133
Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancerÓscar Arrieta|Cancer Medicine|2020Cited by 80
Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: The GERMLUNG studyÓscar Arrieta, Carmen Aláez‐Verson|Lung Cancer|2024Cited by 7
Impact of KRASG12D subtype and concurrent pathogenic mutations on advanced non-small cell lung cancer outcomesEnrique Caballé‐Perez, Óscar Arrieta|Clinical & Translational Oncology|2023Cited by 5